Next Article in Journal
The Role of the 21-Gene Recurrence Score® Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
Next Article in Special Issue
Not All Canadian Cancer Patients Are Equal—Disparities in Public Cancer Drug Funding across Canada
Previous Article in Journal
Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy
Previous Article in Special Issue
Is It Time to Commit to a Process to Re-Evaluate Oncology Drugs? A Descriptive Analysis of Systemic Therapies for Solid Tumour Indications Reviewed in Canada from 2017 to 2021
 
 
Article

Article Versions Notes

Curr. Oncol. 2022, 29(3), 1997-2007; https://doi.org/10.3390/curroncol29030162
Action Date Notes Link
article xml file uploaded 15 March 2022 09:28 CET Original file -
article xml uploaded. 15 March 2022 09:28 CET Update -
article pdf uploaded. 15 March 2022 09:28 CET Version of Record -
article html file updated 15 March 2022 09:29 CET Original file -
article xml file uploaded 15 March 2022 11:01 CET Update -
article xml uploaded. 15 March 2022 11:01 CET Update -
article pdf uploaded. 15 March 2022 11:01 CET Updated version of record -
article xml file uploaded 15 March 2022 11:02 CET Update -
article xml uploaded. 15 March 2022 11:03 CET Update https://www.mdpi.com/1718-7729/29/3/162/xml
article pdf uploaded. 15 March 2022 11:03 CET Updated version of record https://www.mdpi.com/1718-7729/29/3/162/pdf
article html file updated 15 March 2022 11:03 CET Update -
article html file updated 15 March 2022 11:04 CET Update -
article html file updated 1 August 2022 05:43 CEST Update https://www.mdpi.com/1718-7729/29/3/162/html
Back to TopTop